See more : Equitable Holdings, Inc. (EQH-PA) Income Statement Analysis – Financial Results
Complete financial analysis of Intersect ENT, Inc. (XENT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intersect ENT, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Universal Vision Biotechnology Co., Ltd. (3218.TWO) Income Statement Analysis – Financial Results
- Mahalaxmi Rubtech Limited (MHLXMIRU.NS) Income Statement Analysis – Financial Results
- China Nonferrous Metal Industry’s Foreign Engineering and Construction Co.,Ltd. (000758.SZ) Income Statement Analysis – Financial Results
- Hosken Consolidated Investments Limited (HCI.JO) Income Statement Analysis – Financial Results
- Schweitzer-Mauduit International, Inc. (SWM) Income Statement Analysis – Financial Results
Intersect ENT, Inc. (XENT)
About Intersect ENT, Inc.
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 106.75M | 80.55M | 109.14M | 108.47M | 96.30M | 78.71M | 61.59M | 38.59M | 17.93M | 5.86M |
| Cost of Revenue | 30.01M | 30.31M | 21.77M | 22.61M | 15.50M | 13.00M | 12.29M | 10.22M | 8.15M | 3.84M |
| Gross Profit | 76.74M | 50.25M | 87.37M | 85.86M | 80.80M | 65.71M | 49.31M | 28.36M | 9.78M | 2.03M |
| Gross Profit Ratio | 71.89% | 62.38% | 80.05% | 79.15% | 83.91% | 83.48% | 80.05% | 73.51% | 54.55% | 34.56% |
| Research & Development | 27.94M | 19.35M | 24.28M | 19.26M | 18.36M | 18.89M | 16.61M | 10.33M | 9.52M | 9.26M |
| General & Administrative | 0.00 | 98.55M | 108.48M | 91.60M | 80.05M | 72.93M | 59.64M | 36.11M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 122.07M | 98.55M | 108.48M | 91.60M | 80.05M | 72.93M | 59.64M | 36.11M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.23M | 9.25M |
| Operating Expenses | 150.01M | 117.90M | 132.76M | 110.87M | 98.41M | 91.82M | 76.25M | 46.44M | 27.75M | 18.51M |
| Cost & Expenses | 180.02M | 148.21M | 154.54M | 133.48M | 113.90M | 104.82M | 88.53M | 56.67M | 35.90M | 22.35M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 125.00K | 7.00K | 156.00K |
| Interest Expense | 6.44M | 2.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 409.00K | 117.00K | 36.00K |
| Depreciation & Amortization | 4.81M | 2.84M | 3.90M | 1.88M | 1.46M | 1.17M | 826.00K | 583.00K | 505.00K | 351.00K |
| EBITDA | -150.08M | -67.14M | -39.09M | -21.04M | -14.90M | -24.06M | -25.81M | -17.37M | -17.75M | -15.98M |
| EBITDA Ratio | -140.59% | -83.35% | -35.82% | -19.39% | -15.47% | -30.56% | -41.90% | -45.02% | -98.97% | -272.52% |
| Operating Income | -154.89M | -67.65M | -45.39M | -25.01M | -17.60M | -26.11M | -26.94M | -18.08M | -17.97M | -16.49M |
| Operating Income Ratio | -145.10% | -83.98% | -41.59% | -23.05% | -18.28% | -33.17% | -43.74% | -46.85% | -100.20% | -281.17% |
| Total Other Income/Expenses | -6.44M | -5.08M | 2.40M | 2.08M | 1.24M | 889.00K | 306.00K | -284.00K | -403.00K | 120.00K |
| Income Before Tax | -161.33M | -72.74M | -42.99M | -22.92M | -16.36M | -25.22M | -26.63M | -18.36M | -18.37M | -16.37M |
| Income Before Tax Ratio | -151.13% | -90.29% | -39.39% | -21.13% | -16.99% | -32.05% | -43.24% | -47.59% | -102.44% | -279.12% |
| Income Tax Expense | -1.69M | -416.00K | 2.40M | 2.08M | 1.24M | 889.00K | 306.00K | 125.00K | -286.00K | 156.00K |
| Net Income | -159.64M | -72.32M | -42.99M | -22.92M | -16.36M | -25.22M | -26.63M | -18.36M | -18.37M | -16.37M |
| Net Income Ratio | -149.54% | -89.78% | -39.39% | -21.13% | -16.99% | -32.05% | -43.24% | -47.59% | -102.44% | -279.12% |
| EPS | -4.80 | -2.22 | -1.37 | -0.76 | -0.56 | -0.89 | -1.02 | -1.61 | -1.17 | -0.94 |
| EPS Diluted | -4.80 | -2.22 | -1.37 | -0.76 | -0.56 | -0.89 | -1.02 | -1.61 | -1.17 | -0.94 |
| Weighted Avg Shares Out | 33.27M | 32.62M | 31.39M | 30.31M | 29.12M | 28.42M | 26.16M | 11.38M | 15.66M | 17.47M |
| Weighted Avg Shares Out (Dil) | 33.27M | 32.62M | 31.39M | 30.31M | 29.12M | 28.42M | 26.16M | 11.38M | 15.66M | 17.47M |
Intersect ENT Sees Q2 Sales Lag Wall Street Estimates; Raises $60M In Debt Funding
Intersect ENT to Report Second Quarter 2021 Financial Results on August 6
Intersect ENT to Report Second Quarter 2021 Financial Results on August 6
Intersect ENT (XENT) Surges 5.2%: Is This an Indication of Further Gains?
5 Probable MedTech Winners Post-COVID on Discounted PEG
Intersect ENT (XENT) Receives CE Mark for PROPEL Contour
Intersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery
Intersect ENT (XENT) Q1 Loss Wider Than Expected, Revenues Top
Intersect ENT, Inc. (XENT) CEO Tom West on Q1 2021 Results - Earnings Call Transcript
Intersect ENT (XENT) Reports Q1 Loss, Tops Revenue Estimates
Source: https://incomestatements.info
Category: Stock Reports
What were the peak quarterly and annual revenues for Intersect ENT?
Intersect ENT’s peak quarterly revenue was $32.8M in 2018(q4). Intersect ENT peak revenue was $109.1M in 2019. Intersect ENT annual revenue for 2020 was 80.6M, -26.19% growth from 2019. Intersect ENT annual revenue for 2021 was 106.7M, 32.52% growth from 2020.
How did COVID-19 impact Intersect ENT’s financial results?
Through the pandemic months of 2020, Intersect ENT’s business suffered a huge revenue decline as a result of hospitals suspending elective surgical procedures and significantly reducing ENT office visits.